CHIR-124 is a chemical compound that has shown potential as a cancer treatment. It is a small molecule inhibitor of CDK9 which is a protein involved in the regulation of gene transcription. CHIR-124 has been studied in preclinical and clinical trials and has shown promising results in the treatment of various types of cancer. In this article, we will discuss the chemical name, molecular formula, formula weight, and CAS number of CHIR-124. We will also explore the health benefits, mechanism of action, potential effects, safety, side effects, and dosing information for this promising cancer treatment.
Chemical Name: The chemical name of CHIR-124 is (R)-3-(4-chlorophenyl)-N-(1-cyclopropyl-1H-pyrazol-5-yl)-N-((2-methylpropyl)oxy)propanamide.
Molecular Formula: The molecular formula of CHIR-124 is C23H22ClN5O.
Formula Weight: The formula weight of CHIR-124 is 419.91.
CAS No: The CAS number for CHIR-124 is 405168-58-3.
Top Ten Keywords from Google and Synonyms:
Health Benefits of CHIR-124:
CHIR-124 has shown promising results in preclinical studies as a cancer treatment. It has been found to be effective against various types of cancer including breast, lung, colon, and pancreatic cancer. CHIR-124 is a small molecule inhibitor of CDK9, which plays a crucial role in the regulation of gene transcription. Inhibition of CDK9 leads to the suppression of tumor growth and induction of apoptosis (programmed cell death) in cancer cells. Moreover, CHIR-124 has also been found to have anti-angiogenic effects, which means that it can reduce the formation of blood vessels required for tumor growth.
Potential Effects of CHIR-124:
Several preclinical and clinical studies have shown that CHIR-124 has promising anti-tumor effects. In preclinical studies, CHIR-124 has been found to suppress tumor growth, induce apoptosis, and inhibit cell migration and invasion of cancer cells. In clinical trials, CHIR-124 has been found to be safe and tolerable in patients with advanced cancer. It has also shown preliminary evidence of anti-tumor activity in patients with advanced solid tumors. However, further clinical trials are needed to establish the safety and efficacy of CHIR-124 as a cancer treatment.
Product Mechanism:
CHIR-124 is a small molecule inhibitor of CDK9, which is a protein involved in the regulation of gene transcription. CDK9 is a component of the positive transcription elongation factor b (P-TEFb) complex, which stimulates transcription elongation by RNA polymerase II. The CDK9/P-TEFb complex is essential for the expression of genes that promote cell survival and proliferation, including anti-apoptotic genes and oncogenes. Inhibition of CDK9 by CHIR-124 leads to the suppression of tumor growth and induction of apoptosis in cancer cells.
Safety:
CHIR-124 has been found to be safe and well-tolerated in preclinical and clinical studies. However, like any other medication, CHIR-124 can have potential side effects, which may include fatigue, nausea, vomiting, diarrhea, and decreased appetite. Moreover, like other CDK inhibitors, CHIR-124 may also cause hematologic toxicities, such as thrombocytopenia, neutropenia, and anemia. Therefore, careful monitoring of hematologic parameters may be required during treatment with CHIR-124.
Side Effects:
The potential side effects of CHIR-124 may include fatigue, nausea, vomiting, diarrhea, and decreased appetite. Moreover, like other CDK inhibitors, CHIR-124 may also cause hematologic toxicities, such as thrombocytopenia, neutropenia, and anemia. Therefore, careful monitoring of hematologic parameters may be required during treatment with CHIR-124.
Dosing Information:
The optimal dosing of CHIR-124 has not yet been established. However, in preclinical studies, CHIR-124 has been administered orally or intraperitoneally at doses ranging from 10 to 120 mg/kg/day for up to 21 days. In clinical trials, CHIR-124 has been administered orally at doses ranging from 40 to 500 mg/day. The dosing schedules and regimens for CHIR-124 may vary depending on the type of cancer being treated, the stage of the disease, and the patient's overall health and medical history.
Conclusion:
CHIR-124 is a promising cancer treatment that has shown potential in preclinical and clinical trials. It is a small molecule inhibitor of CDK9, which plays a crucial role in the regulation of gene transcription. CHIR-124 has been found to be effective against various types of cancer, including breast, lung, colon, and pancreatic cancer. It has also shown anti-angiogenic effects, which can reduce the formation of blood vessels required for tumor growth. However, like any other medication, CHIR-124 can have potential side effects and careful monitoring of hematologic parameters may be required during treatment. Moreover, further clinical trials are needed to establish the safety and efficacy of CHIR-124 as a cancer treatment.
